Kezar Life Sciences (NASDAQ:KZR) released its earnings results on Thursday. The company reported ($0.30) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.18, MarketWatch Earnings reports.
Shares of KZR stock traded up $0.24 during trading hours on Friday, reaching $24.24. 2,422 shares of the stock were exchanged, compared to its average volume of 65,990. Kezar Life Sciences has a 12-month low of $14.77 and a 12-month high of $26.86.
A number of analysts recently weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Kezar Life Sciences in a research note on Monday, July 16th. They set a “buy” rating and a $23.00 target price on the stock. William Blair assumed coverage on shares of Kezar Life Sciences in a research note on Monday, July 16th. They set an “outperform” rating on the stock. Zacks Investment Research upgraded shares of Kezar Life Sciences from a “sell” rating to a “hold” rating in a research note on Thursday. Wells Fargo & Co assumed coverage on shares of Kezar Life Sciences in a research note on Monday, July 16th. They set an “outperform” rating and a $30.00 target price on the stock. Finally, Cowen assumed coverage on shares of Kezar Life Sciences in a research note on Monday, July 16th. They set an “outperform” rating on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $26.50.
ILLEGAL ACTIVITY WARNING: “Kezar Life Sciences (KZR) Posts Earnings Results, Beats Expectations By $0.18 EPS” was first posted by WKRB News and is the property of of WKRB News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.wkrb13.com/2018/11/09/kezar-life-sciences-kzr-posts-earnings-results-beats-expectations-by-0-18-eps.html.
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Featured Story: Can individual investors take part in an IPO?
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.